Actinium Pharmaceuticals Stock Market Value
| ATNM Stock | USD 1.16 0.07 5.69% |
| Symbol | Actinium |
Will Biotechnology sector continue expanding? Could Actinium diversify its offerings? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Actinium Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.11) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Actinium Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Actinium's accounting equity. The concept of intrinsic value—what Actinium Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Actinium Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Actinium Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actinium Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Actinium Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Actinium Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Actinium Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Actinium Pharmaceuticals.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Actinium Pharmaceuticals on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Actinium Pharmaceuticals or generate 0.0% return on investment in Actinium Pharmaceuticals over 90 days. Actinium Pharmaceuticals is related to or competes with PDS Biotechnology, Xilio Development, Tempest Therapeutics, OnKure Therapeutics, Reviva Pharmaceuticals, Kezar Life, and Tvardi Therapeutics. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing th... More
Actinium Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Actinium Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Actinium Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 20.75 | |||
| Value At Risk | (5.43) | |||
| Potential Upside | 5.84 |
Actinium Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actinium Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Actinium Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Actinium Pharmaceuticals historical prices to predict the future Actinium Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | (0.80) |
Actinium Pharmaceuticals January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.79) | |||
| Mean Deviation | 3.07 | |||
| Coefficient Of Variation | (1,033) | |||
| Standard Deviation | 3.98 | |||
| Variance | 15.85 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | (0.80) | |||
| Maximum Drawdown | 20.75 | |||
| Value At Risk | (5.43) | |||
| Potential Upside | 5.84 | |||
| Skewness | 0.8821 | |||
| Kurtosis | 1.76 |
Actinium Pharmaceuticals Backtested Returns
Actinium Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0515, which signifies that the company had a -0.0515 % return per unit of risk over the last 3 months. Actinium Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Actinium Pharmaceuticals' Risk Adjusted Performance of (0.06), standard deviation of 3.98, and Mean Deviation of 3.07 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Actinium Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Actinium Pharmaceuticals is expected to be smaller as well. At this point, Actinium Pharmaceuticals has a negative expected return of -0.21%. Please make sure to confirm Actinium Pharmaceuticals' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Actinium Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.64 |
Very good reverse predictability
Actinium Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between Actinium Pharmaceuticals time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Actinium Pharmaceuticals price movement. The serial correlation of -0.64 indicates that roughly 64.0% of current Actinium Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.64 | |
| Spearman Rank Test | -0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Actinium Pharmaceuticals Correlation, Actinium Pharmaceuticals Volatility and Actinium Pharmaceuticals Performance module to complement your research on Actinium Pharmaceuticals. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Actinium Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.